How long do improvements usually last and when is maintenance due?
How long do improvements usually last and when is maintenance due? For genitourinary syndrome of menopause (GSM), moisturisers and lubricants soothe quickly but need ongoing use; local vaginal oestrogen or DHEA builds over weeks and is often continued long term; device-based treatments and injectables may help some people for months but are not permanent. Most plans review at 6–12 weeks, 3–6 months, and again at 6–12 months to decide on maintenance. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
How long do improvements usually last and when is maintenance due? Improvements depend on the tool you’re using and whether it addresses the biology and the mechanics of genitourinary syndrome of menopause (GSM). Moisturisers and suitable lubricants reduce friction immediately but only last as long as you keep using them. Local vaginal oestrogen or vaginal DHEA acts on tissue biology; benefits usually appear after 2–6 weeks and are typically maintained with continued use. Energy devices (vaginal laser/radiofrequency) and regenerative injectables (PRP or polynucleotides) may help selected people for months, but effects are not permanent and often soften over time—hence scheduled reviews.
A practical timeline to set expectations. With a disciplined moisturiser routine (many prefer hyaluronic-acid gels) and a compatible lubricant, day-to-day comfort can improve within days, but you’ll need to keep those habits in place. With local vaginal oestrogen/DHEA, tissue re-matures over weeks; many feel a steady step-change by 6–12 weeks, with ongoing benefit while treatment continues. After energy-based care, when it helps, real-world comfort tends to build over several weeks following each session; most pathways use 2–3 sessions 4–8 weeks apart, then reassess. For PRP or polynucleotides, reported gains—when they occur—also appear gradually over weeks and may last months before a review is considered.
Why maintenance is often needed. GSM stems from sustained low oestrogen, so the environment that drives dryness (thinner epithelium, higher pH, reduced Lactobacillus) continues unless you keep supporting it. Think of care like tending a garden: moisturiser/lubricant is regular watering; local hormones are soil health; devices/injectables are optional trellises that may add support but still need water and good soil. As a rule of thumb, we build to comfort, then aim for the lowest effective maintenance that keeps you there.
Suggested review points. 1) 6–12 weeks: judge early change (sting with urine contact, micro-tears at the posterior fourchette, insertional comfort, clothing/walking irritation). 2) 3–6 months: confirm that routines are sustainable and decide whether to adjust dose/format of local therapy or schedule any top-up procedure. 3) 6–12 months: longer-horizon check to ensure comfort is stable; some people choose a single maintenance device/injectable visit, while others do well with foundations alone.
Internal planning resources. For a plain-English overview of how treatment steps are sequenced and transparent notes on inclusions and follow-up intervals under treatment prices, see our clinic pathway pages. These explain where moisturisers/lubricants, local oestrogen/DHEA, device-based options, and injectables fit, and how we decide on review timing.
Four factors that most influence how long improvements last. (1) Foundations: a scheduled moisturiser plus a lubricant that truly suits your needs—water-based (versatile/condom-friendly); silicone-based (long glide if the entrance is tender); oil-based (rich feel but may degrade latex condoms/toys). (2) Targeting: if your pain is entrance-focused, ensure creams are applied to the vestibule and posterior fourchette, not internally only; for procedures, ensure the symptomatic zone is actually treated. (3) Biology support: local oestrogen or DHEA maintains epithelial maturity and healthier pH, helping any gains last longer. (4) Co-drivers: remove irritants (perfumed washes/liners), adjust bike saddles/tight sports kit, rinse chlorine after swimming, and address pelvic floor guarding with physiotherapy and, where useful, graded dilators.
When to bring maintenance forward. If micro-tears or insertional sting start to creep back, first re-check foundations and placement. If you’re on local hormones, check that your dose and technique still suit you (a fingertip to the vestibule can be pivotal). If devices/injectables helped earlier but symptoms gradually return, consider whether a single top-up is worthwhile after revisiting the basics—sometimes switching to a silicone-based lubricant or optimising local therapy outperforms another procedure.
When to pause and reassess. If progress stalls or reverses, pause procedures and review diagnosis: “dryness” can mask BV/thrush, UTIs, contact dermatitis, or dermatoses like lichen sclerosus. Red flags—malodorous green/grey discharge, intense itch with thick white discharge, fever, visible blood in urine, or new post-menopausal bleeding—need prompt assessment before continuing.
Clinical Context
Who tends to enjoy longer-lasting improvements? People who keep a consistent moisturiser routine, use a generous, compatible lubricant for higher-friction moments, and—if acceptable—continue local vaginal oestrogen/DHEA. Those who target the vestibule precisely (with fingertip-applied creams or procedure placement) and reduce everyday irritants also tend to need fewer top-ups.
Who may notice quicker fade? Anyone with ongoing irritants (fragranced washes/liners, tight synthetic kit, chlorine without rinsing), mis-targeted care (internal-only when the pain is at the entrance), untreated infections, or prominent pelvic floor guarding after painful sex. In these cases, maintenance is less about repeating procedures and more about getting the basics and diagnosis right.
Next steps you can action now. Keep cleansing gentle (lukewarm water; bland emollient as a soap substitute), choose breathable underwear, and schedule moisturiser 2–4 times weekly. If penetration is the main trigger, a silicone-based lubricant often gives the longest glide. Consider pelvic health physiotherapy if fear of pain is sustaining muscle tension. Plan reviews at 6–12 weeks and 3–6 months to adjust towards the lowest effective maintenance plan.
Evidence-Based Approaches
Guideline first lines (UK): Patient-friendly advice on symptoms, self-care and red flags appears on the NHS page for vaginal dryness. The NICE Menopause Guideline (NG23) recommends offering information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life.
Product and prescribing detail: UK product information and cautions for local therapies (vaginal oestrogens, prasterone/DHEA) are listed in the British National Formulary (BNF), supporting long-term, low-dose maintenance strategies when appropriate.
Comparators with robust evidence: Systematic reviews in the Cochrane Library show that local vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo across creams, tablets/pessaries and rings, with benefits maintained during continued use.
Pathophysiology and timelines: Peer-reviewed overviews indexed on PubMed explain GSM mechanisms (thinner epithelium, higher pH, reduced lactobacilli) and why local hormonal therapy provides sustained benefit, while device/injectable effects are adjunctive and time-limited without foundations.
Applying the evidence: Maintain foundations, use local therapy for biology where acceptable, and treat devices/injectables as selective adjuncts. Schedule reviews at 6–12 weeks, 3–6 months and 6–12 months to decide on maintenance or de-escalation, aiming for the lowest effective plan over time.